FILING ANALYSIS · FRIDAY, NOVEMBER 13
PAVmed Inc. PAVM — 8-K: Results of Operations and Financial Condition
neutral
PAVmed Inc. reported preliminary third quarter 2026 financial results, with Lucid Diagnostics' EsoGuard now fully reimbursed by Medicare nationwide, and provided a business update on its subsidiaries, including progress on Veris Health's implantable physiological monitor and FDA engagement for PortIO and Octeris, but no quantified surprises were disclosed beyond the Medicare reimbursement for EsoG
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →